Molecular Tumor Board

The Markey Cancer Center Molecular Tumor Board (MTB) is a statewide service available to physicians at UK HealthCare and regional affiliates.

The MTB provides a forum for expert clinicians, pathologists and scientists to discuss and analyze tumor genotypes and molecular abnormalities in order to recommend patient-specific targeted therapies. 

The MTB is intended to supplement oncology tumor boards and includes a broad range of expert panel members.

Clinicians can order a genomic report and submit a case study to be presented for review by the MTB during their twice-monthly meetings.

The Molecular Tumor Board (MTB) meets at 12:00pm on the first and third Tuesday of each month.

MTB meetings are currently held virtually via OncoLens. Please email either Abigail Anderson, PhD or Rebecca Carpenter for details to attend.

Some MTB meetings will include a 15-minute informational update on Precision Medicine. 

To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to the meeting date.

Continuing Medical Education (CME)

If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the live meeting then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at

Policy on Disclosure

It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

Cases must be submitted at least seven days prior to the meeting date.

Genomics reports from any testing laboratory (Caris, Foundation, Guardant, Tempus, etc.) can be submitted. A patient's genomic report is required for case submission. 

When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed, sent by secure e-mail, mailed or uploaded into the electronic health record per the preference of the submitting physician.Specify method of results reporting on the case submission form.

Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

The molecular tumor board will review genomic reports from any testing laboratory. If you need assistance with ordering genomic testing, please reach out to your laboratory representative. You can contact the MTB if you have general questions.

Genomic reports for patients with hematologic malignancies can be ordered through the Clinical Molecular and Genomic Pathology department. There are some gene-specific hematological panels as well as a larger hematological malignancy panel.

Please see more information about our clinical genomics laboratory by visiting the department's website.

Guidance documents are used to establish guidelines for Molecular Tumor Board (MTB) recommendations for advanced cancer.

MTB guidance documents will be made available to download below.

Download Guidance MTB Documents

Reference documents are used to aid Molecular Tumor Board members in meeting discussions and advanced care recommendations.

MTB reference documents will be made available for download below on this page.

Download MTB Documents

Watch MTB presentations

The Molecular Tumor Board currently has three prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

  • MULTI-19 Part 1: A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
  • MULTI-19 Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.
  • PRiMAL: A prospective study for patients with newly-diagnosed non-small cell lung cancer (NSCLC) evaluating outcomes for patients undergoing usual care compared to those where the MTB is actively involved in patients’ care.

Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.




Dr. Jill KolesarJill M. Kolesar, PharmD, MS
Dr. Michael E. Karpf Endowed Chair 
University Research Professor, Colleges of
Pharmacy and Medicine
Co-Leader, Translational Oncology
Research Program


Rachel Ware MillerRachel Ware Miller, MD
Professor of Obstetrics and Gynecology
Division of Gynecologic Oncology


Assistant Director

Justine C. Pickarski, MS, LGC
Licensed Genetic Counselor

MTB Nurse Navigator

Kelly Tucker, RN, BSN, OCN

Administrative Office

Abigail Anderson, PhD
MTB Project Manager


Rebecca Carpenter
Administrative Staff Officer

Related Stories

NCI Comprehensive Cancer Center - A Cancer Center Designated by the National Cancer Institute

Markey Cancer Center is designated by the National Cancer Institute as a Comprehensive Cancer Center – a distinction that recognizes our commitment to accelerating precision cancer research and care to patients. We are the first and only NCI-Comprehensive Cancer Center in Kentucky, and one of 57 in the nation.